Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at ...

Shares of CureVac are trading higher by 13.5% during Monday's session. The stock is gaining following a CDC report highlighting a significant increase in acute respiratory illnesses nationwide.

Shares of CureVac fell by 12.3% Wednesday afternoon. The pullback may stem from profit-taking after Tuesday's strong gains driven by rising concerns over U.S. respiratory illnesses. Get Wall ...

CureVac (NASDAQ:CVAC – Free Report) – Stock analysts at Leerink Partnrs upped their FY2025 earnings estimates for shares of CureVac in a note issued to investors on Wednesday, January 22nd.

CureVac (NASDAQ:CVAC) was able to report positive data from Part A of its phase 1 study using its vaccine candidate CVGBM for the treatment of patients with HLA-*02:01-positive patients with newly ...

The Amsterdam UMC has sued Ronald Plasterk and the biotech firm CureVac for failing to credit the hospital and its scientist, Jan Koster, in patents around the development of cancer vaccines.

Pfizer and its German partner BioNTech on Tuesday won their attempt to invalidate two of rival CureVac's patents at London's High Court. Pfizer, BioNTech win bid to invalidate CureVac's UK COVID ...

Amsterdam’s UMC teaching hospital is taking former Labour minister and PVV prime ministerial hopeful Ronald Plasterk to court ...

GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory infections, paying €400 million ($429 million) upfront for global rights to its influenza and COVID ...